CytomX Therapeutics, a clinical-stage biopharmaceutical company based in South San Francisco, develops conditionally activated biologics for oncology, with a pipeline including CX-904 and CX-2051. The company went public on October 8, 2015, and has 120 employees.
CytomX Therapeutics (CTMX) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, CytomX Therapeutics's actual EPS was $0.23, beating the estimate of -$0.20 per share, resulting in a 215.23% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
